By vgreene, 5 February, 2020 Notify infxn control and health dept; test via RT-PCR; avoid delays in shipping lab specimens
By vgreene, 5 February, 2020 For biosafety reasons, it is not recommended to perform virus isolation in cell culture or initial characterization of viral agents recovered in cultures of specimens from a PUI for 2019-nCoV
By vgreene, 5 February, 2020 Don’t delay shipping specimen to CDC while testing for other resp pathogens. If PUI tests positive for another resp pathogen, after clinical eval and consultation w/ public health authorities, they may no longer be considered a PUI. This may evolve as mor
By vgreene, 5 February, 2020 Currently, 2019-nCoV infxn is confirmed by CDC via real-time RT-PCR assay on resp specimens (incl nasopharyngeal or oropharyngeal aspirates or washes, nasopharyngeal or oropharyngeal swabs, broncheoalveolar lavage, tracheal aspirates, or sputum) and serum
By vgreene, 5 February, 2020 Immediately notify healthcare facility’s infxn control personnel and local/state health dept in event of PUI for 2019-nCoV
By vgreene, 5 February, 2020 Notify infxn control and health dept; test via RT-PCR; avoid delays in shipping lab specimens
By vgreene, 5 February, 2020 Chest CT images: bilateral involvement in most pts; multiple areas of consolidation and ground glass opacities are typical findings reported to date